NSRX
Nasus Pharma Ltd.
There isn't enough reported data to score NSRX yet.
NSRX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
NSRX's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
NSRX PE Valuation
NSRX has no meaningful PE right now: it lost money over the past year.
NSRX Forward outlook
There aren't enough analyst estimates for NSRX to show an outlook.
NSRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$0.72 | -$0.50 |
| Q2 2025 | -$0.26 | -$0.01 |
| Q4 2024 | -$0.22 | -$0.01 |
NSRX lost $0.72 per share over the past year, a bigger loss than the year before.
NSRX Quarterly Revenue
NSRX's revenue is shrinking: $0 last quarter.
NSRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | -$242 | +$34 |
| Q3 2024 | -$242 | +$34 |
| Q2 2024 | -$90 | +$148 |
| Q1 2024 | -$90 | +$148 |
NSRX has burned cash in almost every quarter: −$664 over the past year, against −$1,028 the year before.
NSRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +8.8% | +647K shares |
| 1 year | +16% | +1.1M shares |
NSRX has 8M diluted shares, up 16% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
NSRX Net Leverage
NSRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NSRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.5 | Neutral |
| Stochastic | 6.7 | Oversold |
NSRX's weekly RSI is 41 (neutral) and its Stochastic is 7 (oversold).
NSRX PE vs Healthcare Sector
NSRX has no meaningful PE right now: it lost money over the past year.
NSRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.29 | 14% below |
| 20 week MA | $3.39 | 17% below |
| 50 week MA | $4.09 | 31% below |
NSRX is in a downtrend: it's below all three of its weekly moving averages, and 31% below its 50-week average.
NSRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $8.10 | $7.61 | -6% |
| 2026 YTD | $7.61 | $2.82 | -63% |
NSRX has finished every year since 2025 lower, and it's down 63% so far in 2026.